カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界の経口血糖降下薬市場2022年：スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤

◆英語タイトル：Global Oral Hypoglycemic Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	◆商品コード：GIR22MY8913 ◆発行会社（リサーチ会社）：GlobalInfoResearch ◆発行日：2022年5月（※2025年版があります。お問い合わせください。） ◆ページ数：102 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（注文後2-3日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥528,960	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥793,440	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,057,920	見積依頼/購入/質問フォーム

★GlobalInfoResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

経口血糖降下薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の経口血糖降下薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

経口血糖降下薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤

用途別セグメントは次のように区分されます。
・病院、クリニック、その他

世界の経口血糖降下薬市場の主要な市場プレーヤーは以下のとおりです。
・Pfizer、AstraZeneca、Johnson & Johnson、GlaxoSmithKline、Merck & Co、Eli Lilly、Sanofi、Takeda Pharmaceuticals、Novo Nordisk、Servier Laboratories、Boehringer Ingelheim、Bristol-Myers Squibb

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、経口血糖降下薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な経口血糖降下薬メーカーの企業概要、2019年～2022年までの経口血糖降下薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な経口血糖降下薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別経口血糖降下薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの経口血糖降下薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での経口血糖降下薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および経口血糖降下薬の産業チェーンを掲載しています。
・第13、14、15章では、経口血糖降下薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、AstraZeneca、Johnson & Johnson、GlaxoSmithKline、Merck & Co、Eli Lilly、Sanofi、Takeda Pharmaceuticals、Novo Nordisk、Servier Laboratories、Boehringer Ingelheim、Bristol-Myers Squibb
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤
・用途別分析2017年-2028年：病院、クリニック、その他
・経口血糖降下薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・経口血糖降下薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・経口血糖降下薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・経口血糖降下薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・経口血糖降下薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Oral Hypoglycemic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Oral Hypoglycemic Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Oral Hypoglycemic Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Sulfonylureas (SU) segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Oral Hypoglycemic Drugs include Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, and Merck & Co, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Oral Hypoglycemic Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Sulfonylureas (SU)
Double Guanidine
Glucosidase Inhibitor
Insulin Synergist
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Oral Hypoglycemic Drugs market are listed below:
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Hypoglycemic Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oral Hypoglycemic Drugs, with price, sales, revenue and global market share of Oral Hypoglycemic Drugs from 2019 to 2022.
Chapter 3, the Oral Hypoglycemic Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Hypoglycemic Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Oral Hypoglycemic Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oral Hypoglycemic Drugs.
Chapter 13, 14, and 15, to describe Oral Hypoglycemic Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Oral Hypoglycemic Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oral Hypoglycemic Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Sulfonylureas (SU)
1.2.3 Double Guanidine
1.2.4 Glucosidase Inhibitor
1.2.5 Insulin Synergist
1.3 Market Analysis by Application
1.3.1 Overview: Global Oral Hypoglycemic Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Oral Hypoglycemic Drugs Market Size & Forecast
1.4.1 Global Oral Hypoglycemic Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Oral Hypoglycemic Drugs Sales in Volume (2017-2028)
1.4.3 Global Oral Hypoglycemic Drugs Price (2017-2028)
1.5 Global Oral Hypoglycemic Drugs Production Capacity Analysis
1.5.1 Global Oral Hypoglycemic Drugs Total Production Capacity (2017-2028)
1.5.2 Global Oral Hypoglycemic Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oral Hypoglycemic Drugs Market Drivers
1.6.2 Oral Hypoglycemic Drugs Market Restraints
1.6.3 Oral Hypoglycemic Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Oral Hypoglycemic Drugs Product and Services
2.1.4 Pfizer Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Oral Hypoglycemic Drugs Product and Services
2.2.4 AstraZeneca Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Oral Hypoglycemic Drugs Product and Services
2.3.4 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Product and Services
2.4.4 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Merck & Co
2.5.1 Merck & Co Details
2.5.2 Merck & Co Major Business
2.5.3 Merck & Co Oral Hypoglycemic Drugs Product and Services
2.5.4 Merck & Co Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Oral Hypoglycemic Drugs Product and Services
2.6.4 Eli Lilly Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Oral Hypoglycemic Drugs Product and Services
2.7.4 Sanofi Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Takeda Pharmaceuticals
2.8.1 Takeda Pharmaceuticals Details
2.8.2 Takeda Pharmaceuticals Major Business
2.8.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product and Services
2.8.4 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Novo Nordisk
2.9.1 Novo Nordisk Details
2.9.2 Novo Nordisk Major Business
2.9.3 Novo Nordisk Oral Hypoglycemic Drugs Product and Services
2.9.4 Novo Nordisk Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Servier Laboratories
2.10.1 Servier Laboratories Details
2.10.2 Servier Laboratories Major Business
2.10.3 Servier Laboratories Oral Hypoglycemic Drugs Product and Services
2.10.4 Servier Laboratories Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business
2.11.3 Boehringer Ingelheim Oral Hypoglycemic Drugs Product and Services
2.11.4 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Bristol-Myers Squibb
2.12.1 Bristol-Myers Squibb Details
2.12.2 Bristol-Myers Squibb Major Business
2.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Product and Services
2.12.4 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Oral Hypoglycemic Drugs Breakdown Data by Manufacturer
3.1 Global Oral Hypoglycemic Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Oral Hypoglycemic Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Oral Hypoglycemic Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Oral Hypoglycemic Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Oral Hypoglycemic Drugs Manufacturer Market Share in 2021
3.5 Global Oral Hypoglycemic Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Oral Hypoglycemic Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oral Hypoglycemic Drugs Market Size by Region
4.1.1 Global Oral Hypoglycemic Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Oral Hypoglycemic Drugs Revenue by Region (2017-2028)
4.2 North America Oral Hypoglycemic Drugs Revenue (2017-2028)
4.3 Europe Oral Hypoglycemic Drugs Revenue (2017-2028)
4.4 Asia-Pacific Oral Hypoglycemic Drugs Revenue (2017-2028)
4.5 South America Oral Hypoglycemic Drugs Revenue (2017-2028)
4.6 Middle East and Africa Oral Hypoglycemic Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Oral Hypoglycemic Drugs Sales in Volume by Type (2017-2028)
5.2 Global Oral Hypoglycemic Drugs Revenue by Type (2017-2028)
5.3 Global Oral Hypoglycemic Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Oral Hypoglycemic Drugs Sales in Volume by Application (2017-2028)
6.2 Global Oral Hypoglycemic Drugs Revenue by Application (2017-2028)
6.3 Global Oral Hypoglycemic Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Oral Hypoglycemic Drugs Sales by Type (2017-2028)
7.2 North America Oral Hypoglycemic Drugs Sales by Application (2017-2028)
7.3 North America Oral Hypoglycemic Drugs Market Size by Country
7.3.1 North America Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Oral Hypoglycemic Drugs Sales by Type (2017-2028)
8.2 Europe Oral Hypoglycemic Drugs Sales by Application (2017-2028)
8.3 Europe Oral Hypoglycemic Drugs Market Size by Country
8.3.1 Europe Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Oral Hypoglycemic Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Oral Hypoglycemic Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Oral Hypoglycemic Drugs Market Size by Region
9.3.1 Asia-Pacific Oral Hypoglycemic Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Oral Hypoglycemic Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Oral Hypoglycemic Drugs Sales by Type (2017-2028)
10.2 South America Oral Hypoglycemic Drugs Sales by Application (2017-2028)
10.3 South America Oral Hypoglycemic Drugs Market Size by Country
10.3.1 South America Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oral Hypoglycemic Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Oral Hypoglycemic Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Oral Hypoglycemic Drugs Market Size by Country
11.3.1 Middle East & Africa Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Oral Hypoglycemic Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Oral Hypoglycemic Drugs
12.3 Oral Hypoglycemic Drugs Production Process
12.4 Oral Hypoglycemic Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Oral Hypoglycemic Drugs Typical Distributors
13.3 Oral Hypoglycemic Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Oral Hypoglycemic Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Oral Hypoglycemic Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Oral Hypoglycemic Drugs Product and Services
Table 6. Pfizer Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Major Business
Table 9. AstraZeneca Oral Hypoglycemic Drugs Product and Services
Table 10. AstraZeneca Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 12. Johnson & Johnson Major Business
Table 13. Johnson & Johnson Oral Hypoglycemic Drugs Product and Services
Table 14. Johnson & Johnson Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 16. GlaxoSmithKline Major Business
Table 17. GlaxoSmithKline Oral Hypoglycemic Drugs Product and Services
Table 18. GlaxoSmithKline Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 20. Merck & Co Major Business
Table 21. Merck & Co Oral Hypoglycemic Drugs Product and Services
Table 22. Merck & Co Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 24. Eli Lilly Major Business
Table 25. Eli Lilly Oral Hypoglycemic Drugs Product and Services
Table 26. Eli Lilly Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Sanofi Basic Information, Manufacturing Base and Competitors
Table 28. Sanofi Major Business
Table 29. Sanofi Oral Hypoglycemic Drugs Product and Services
Table 30. Sanofi Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Takeda Pharmaceuticals Major Business
Table 33. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product and Services
Table 34. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 36. Novo Nordisk Major Business
Table 37. Novo Nordisk Oral Hypoglycemic Drugs Product and Services
Table 38. Novo Nordisk Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Servier Laboratories Basic Information, Manufacturing Base and Competitors
Table 40. Servier Laboratories Major Business
Table 41. Servier Laboratories Oral Hypoglycemic Drugs Product and Services
Table 42. Servier Laboratories Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 44. Boehringer Ingelheim Major Business
Table 45. Boehringer Ingelheim Oral Hypoglycemic Drugs Product and Services
Table 46. Boehringer Ingelheim Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 48. Bristol-Myers Squibb Major Business
Table 49. Bristol-Myers Squibb Oral Hypoglycemic Drugs Product and Services
Table 50. Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global Oral Hypoglycemic Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 52. Global Oral Hypoglycemic Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in Oral Hypoglycemic Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global Oral Hypoglycemic Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 55. Head Office and Oral Hypoglycemic Drugs Production Site of Key Manufacturer
Table 56. Oral Hypoglycemic Drugs New Entrant and Capacity Expansion Plans
Table 57. Oral Hypoglycemic Drugs Mergers & Acquisitions in the Past Five Years
Table 58. Global Oral Hypoglycemic Drugs Sales by Region (2017-2022) & (K Units)
Table 59. Global Oral Hypoglycemic Drugs Sales by Region (2023-2028) & (K Units)
Table 60. Global Oral Hypoglycemic Drugs Revenue by Region (2017-2022) & (USD Million)
Table 61. Global Oral Hypoglycemic Drugs Revenue by Region (2023-2028) & (USD Million)
Table 62. Global Oral Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 63. Global Oral Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 64. Global Oral Hypoglycemic Drugs Revenue by Type (2017-2022) & (USD Million)
Table 65. Global Oral Hypoglycemic Drugs Revenue by Type (2023-2028) & (USD Million)
Table 66. Global Oral Hypoglycemic Drugs Price by Type (2017-2022) & (US$/Unit)
Table 67. Global Oral Hypoglycemic Drugs Price by Type (2023-2028) & (US$/Unit)
Table 68. Global Oral Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 69. Global Oral Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Global Oral Hypoglycemic Drugs Revenue by Application (2017-2022) & (USD Million)
Table 71. Global Oral Hypoglycemic Drugs Revenue by Application (2023-2028) & (USD Million)
Table 72. Global Oral Hypoglycemic Drugs Price by Application (2017-2022) & (US$/Unit)
Table 73. Global Oral Hypoglycemic Drugs Price by Application (2023-2028) & (US$/Unit)
Table 74. North America Oral Hypoglycemic Drugs Sales by Country (2017-2022) & (K Units)
Table 75. North America Oral Hypoglycemic Drugs Sales by Country (2023-2028) & (K Units)
Table 76. North America Oral Hypoglycemic Drugs Revenue by Country (2017-2022) & (USD Million)
Table 77. North America Oral Hypoglycemic Drugs Revenue by Country (2023-2028) & (USD Million)
Table 78. North America Oral Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 79. North America Oral Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 80. North America Oral Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 81. North America Oral Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 82. Europe Oral Hypoglycemic Drugs Sales by Country (2017-2022) & (K Units)
Table 83. Europe Oral Hypoglycemic Drugs Sales by Country (2023-2028) & (K Units)
Table 84. Europe Oral Hypoglycemic Drugs Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe Oral Hypoglycemic Drugs Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe Oral Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 87. Europe Oral Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 88. Europe Oral Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Europe Oral Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 90. Asia-Pacific Oral Hypoglycemic Drugs Sales by Region (2017-2022) & (K Units)
Table 91. Asia-Pacific Oral Hypoglycemic Drugs Sales by Region (2023-2028) & (K Units)
Table 92. Asia-Pacific Oral Hypoglycemic Drugs Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific Oral Hypoglycemic Drugs Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific Oral Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 95. Asia-Pacific Oral Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 96. Asia-Pacific Oral Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 97. Asia-Pacific Oral Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 98. South America Oral Hypoglycemic Drugs Sales by Country (2017-2022) & (K Units)
Table 99. South America Oral Hypoglycemic Drugs Sales by Country (2023-2028) & (K Units)
Table 100. South America Oral Hypoglycemic Drugs Revenue by Country (2017-2022) & (USD Million)
Table 101. South America Oral Hypoglycemic Drugs Revenue by Country (2023-2028) & (USD Million)
Table 102. South America Oral Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 103. South America Oral Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 104. South America Oral Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 105. South America Oral Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 106. Middle East & Africa Oral Hypoglycemic Drugs Sales by Region (2017-2022) & (K Units)
Table 107. Middle East & Africa Oral Hypoglycemic Drugs Sales by Region (2023-2028) & (K Units)
Table 108. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa Oral Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 111. Middle East & Africa Oral Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 112. Middle East & Africa Oral Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 113. Middle East & Africa Oral Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 114. Oral Hypoglycemic Drugs Raw Material
Table 115. Key Manufacturers of Oral Hypoglycemic Drugs Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. Oral Hypoglycemic Drugs Typical Distributors
Table 119. Oral Hypoglycemic Drugs Typical Customers
List of Figures
Figure 1. Oral Hypoglycemic Drugs Picture
Figure 2. Global Oral Hypoglycemic Drugs Revenue Market Share by Type in 2021
Figure 3. Sulfonylureas (SU)
Figure 4. Double Guanidine
Figure 5. Glucosidase Inhibitor
Figure 6. Insulin Synergist
Figure 7. Global Oral Hypoglycemic Drugs Revenue Market Share by Application in 2021
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global Oral Hypoglycemic Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Oral Hypoglycemic Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Oral Hypoglycemic Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Oral Hypoglycemic Drugs Price (2017-2028) & (US$/Unit)
Figure 15. Global Oral Hypoglycemic Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Oral Hypoglycemic Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Oral Hypoglycemic Drugs Market Drivers
Figure 18. Oral Hypoglycemic Drugs Market Restraints
Figure 19. Oral Hypoglycemic Drugs Market Trends
Figure 20. Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Oral Hypoglycemic Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Oral Hypoglycemic Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Oral Hypoglycemic Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Oral Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Oral Hypoglycemic Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Oral Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Oral Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Oral Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Oral Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Oral Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Oral Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Oral Hypoglycemic Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 35. Global Oral Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Oral Hypoglycemic Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 38. North America Oral Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Oral Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Oral Hypoglycemic Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Oral Hypoglycemic Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Oral Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Oral Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Oral Hypoglycemic Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Oral Hypoglycemic Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Oral Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Oral Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Oral Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Oral Hypoglycemic Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Oral Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Oral Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Oral Hypoglycemic Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Oral Hypoglycemic Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Oral Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Oral Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Oral Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Oral Hypoglycemic Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Oral Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Oral Hypoglycemic Drugs in 2021
Figure 79. Manufacturing Process Analysis of Oral Hypoglycemic Drugs
Figure 80. Oral Hypoglycemic Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の経口血糖降下薬市場2022年：スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤(Global Oral Hypoglycemic Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の経口血糖降下薬市場2022年：スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp